Latest & greatest articles for Alcoholic Hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Alcoholic Hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Alcoholic Hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Alcoholic Hepatitis

41. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. Full Text available with Trip Pro

Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. Mortality among patients with severe acute alcoholic hepatitis is high, even among those treated with glucocorticoids. We investigated whether combination therapy with glucocorticoids plus N-acetylcysteine would improve survival.We randomly assigned 174 patients to receive prednisolone plus N-acetylcysteine (85 patients) or only prednisolone (89 patients). All patients received 4 weeks of prednisolone. The prednisolone-N (...) combination therapy with prednisolone plus N-acetylcysteine increased 1-month survival among patients with severe acute alcoholic hepatitis, 6-month survival, the primary outcome, was not improved. (Funded by Programme Hospitalier de Recherche Clinique; AAH-NAC ClinicalTrials.gov number, NCT00863785 .).

2011 NEJM Controlled trial quality: predicted high

42. A New Scoring System for Prognostic Stratification of Patients With Alcoholic Hepatitis (Abstract)

A New Scoring System for Prognostic Stratification of Patients With Alcoholic Hepatitis Prognostic stratification of patients with alcoholic hepatitis (AH) may improve the clinical management and facilitate clinical trials. We aimed at developing a scoring system capable of providing prognostic stratification of patients with AH.Patients with biopsy-proven AH were prospectively included between 2000 and 2006. The biochemical, clinical, portal hemodynamic and histological parameters were

2008 EvidenceUpdates

43. Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials Full Text available with Trip Pro

Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials Glucocorticosteroids versus placebo or no intervention for patients with alcoholic hepatitis have been evaluated for more than 35 years. However, the results of randomized trials and meta-analyses differ substantially.To review all randomized clinical trials of glucocorticosteroids vs. placebo (...) evidence base of mainly heterogeneous with high bias risk trials does not support the use of glucocorticosteroids in alcoholic hepatitis. Large, low-bias risk placebo-controlled randomized trials are needed.

2008 EvidenceUpdates

44. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables

Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables Christensen E, Gluud C Authors' objectives To perform a meta-analysis of controlled clinical trials of glucocorticoid treatment in alcoholic hepatitis, adjusting (...) a description of patient characteristics separately for both treatment groups were included. Specific interventions included in the review Glucocorticosteroid therapy versus placebo or no active drug control in patients with alcoholic hepatitis. The specific steroids used in the studies were: prednisolone, methylprednisolone and prednisone. Participants included in the review Patients with alcoholic hepatitis were included. Outcomes assessed in the review The outcome was mortality up to 2.5 months after

1995 DARE.

45. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. (Abstract)

A randomized trial of prednisolone in patients with severe alcoholic hepatitis. Controlled trials have yielded inconsistent results with regard to the efficacy of corticosteroids in the treatment of alcoholic hepatitis. Three meta-analyses suggest that they may be effective in patients with encephalopathy who have severe liver disease.We conducted a randomized, double-blind trial comparing 28 days of prednisolone treatment (40 mg per day) with placebo in 61 patients with biopsy-proved alcoholic (...) biopsy-proved alcoholic hepatitis.

1992 NEJM Controlled trial quality: predicted high

46. Safety of alcohol after viral hepatitis. (Abstract)

Safety of alcohol after viral hepatitis. To test the validity of the generally held belief that moderate consumption of alcohol during convalescence from acute viral hepatitis adversely affects outcome, 87 adults recovering from acute viral hepatitis (hepatitis A in 36, hepatitis B in 34, hepatitis non-A, non-B in 17) were studied. Criteria for entry to the study attempted to ensure that no patient was a chronic hepatitis B carrier. Patients were randomised either to a moderate alcohol intake (...) , or to continued complete abstention. Drinkers consumed 26 g alcohol daily (mean) and none remained abstinent. At 3 months all patients were well, with normal liver function tests. There were no significant differences between the two groups at anytime. The findings suggest that moderate alcohol intake during convalescence from acute viral hepatitis does not seem to be harmful.

1991 Lancet Controlled trial quality: uncertain

47. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. (Abstract)

Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. A cooperative study was conducted to determine the efficacy of 30 days of treatment with either a glucocorticosteroid (prednisolone) or an anabolic steroid (oxandrolone) in moderate or severe alcoholic hepatitis. One hundred thirty-two patients with moderate disease and 131 with severe disease were randomly assigned to one of three treatments: prednisolone, oxandrolone, or placebo

1984 NEJM Controlled trial quality: uncertain

48. Aminoacid therapy of alcoholic hepatitis. (Abstract)

Aminoacid therapy of alcoholic hepatitis. 35 consecutive patients with alcoholic hepatitis were randomly allocated to control (18 patients) and study (17 patients) groups. All patients were offered a 3000 kcal 100 g protein diet and were studied for 28 days. The study group received 70-85 g of intravenous aminoacids daily in the form of 'Aminosyn' or 'Travasol'. Both groups had similar clinical and biochemical features at the time of randomisation. Ascites and encephalopathy tended to improve (...) more in the study group. Serum concentrations of bilirubin (p < 0.01) and albumin (p < 0.025) improved in the study but not in the control group. 4 patients died in the control group, but none died in the study group. Intravenous therapy with aminoacid for 4 weeks seemed to be associated with lower mortality rate (p < 0.02) and improved serum bilirubin and albumin concentrations in patients with alcoholic hepatitis.

1980 Lancet Controlled trial quality: uncertain

49. Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. (Abstract)

Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. 4751740 1974 01 15 2016 11 23 0003-4819 79 5 1973 Nov Annals of internal medicine Ann. Intern. Med. Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. 625-31 Campra J L JL Hamlin E M EM Jr Kirshbaum R J RJ Olivier M M Redeker A G AG Reynolds T B TB eng Clinical Trial Journal Article Randomized Controlled Trial United States Ann Intern Med 0372351 0003-4819 0 Serum Albumin EC 2.6.1.1 (...) Aspartate Aminotransferases RFM9X3LJ49 Bilirubin VB0R961HZT Prednisone AIM IM Acute Disease Adult Alcoholism complications Aspartate Aminotransferases blood Bilirubin blood California Chemical and Drug Induced Liver Injury drug therapy etiology mortality Female Hospitalization Humans Length of Stay Male Middle Aged Prednisone administration & dosage therapeutic use Prothrombin Time Serum Albumin metabolism Time Factors 1973 11 1 2001 3 28 10 1 1973 11 1 0 0 ppublish 4751740

1974 Annals of Internal Medicine Controlled trial quality: uncertain